Accustem Sciences Inc.

UNDERVALUEDACUT · OTC · Healthcare
ACUT·OTC·Healthcare
UNDERVALUED
Accustem Sciences Inc.
41.7%upside
MARKET PRICE
$0.36
FAIR PRICE
$0.51
MARGIN
$0.15
UNDERVALUEDFAIROVERVALUED
P/E RATIO
N/A
DIV. YIELD
N/A
ROE
59.1%
MARKET CAP
$6M
FPI
fairpriceindex.com

FAIR PRICE VALUATION

41.7%upside

Updated daily

Model: DCF 50% · Relative 30% · Consensus 20%

MARKET PRICE

$0.36

FAIR PRICE

$0.51

MARGIN

$0.15

UNDERVALUEDFAIROVERVALUED

P/E Ratio

N/A

Div. Yield

N/A

ROE

59.1%

Exceptional

Market Cap

$6M

Small-cap

FPI RATING

2.1/ 10

High-quality fundamentals and low debt levels, but weak profitability margins and volatile earnings pattern.

Analytical data, not an investment recommendation. Updated daily.

How we calculate this ↗

MARGIN OF SAFETY

A 20% margin of safety below fair value — the conservative entry level for risk-aware investors.

$0.41CONSERVATIVE ENTRY
$0.51FAIR PRICE
$0.36MARKET PRICE

SAFETY MARGIN

20%

Below fair value

ENTRY LEVEL

$0.41

Fair price × 0.80

DISTANCE

13.3%

Price to entry level

At the current price of $0.36, ACUT trades 13.3% below the conservative entry level of $0.41. The stock is currently priced below the 20% margin of safety threshold, indicating a potential value opportunity based on the model.

Margin of safety is a risk management concept, not an investment recommendation. The 20% threshold follows Benjamin Graham's value investing framework. Fair price and entry levels are model-based estimates updated daily. Learn more about Margin of Safety ↗

VALUATION HISTORY

Loading chart data...

COMING SOON

Get notified when ACUT's fair price changes

Fair Price Index app is launching soon with push notifications when valuations shift for stocks you follow.

iOS and Android · Free tier available

KEY FACTS

CEO

Wendy E. Blosser

COUNTRY

US

HEADQUARTERS

New York City

SECTOR

Healthcare

EXCHANGE

OTC

METHODOLOGY

How we calculate ACUT's fair price

Accustem Sciences Inc.'s fair price of $0.51 is derived from a blended model that combines DCF analysis (50%), relative valuation against Healthcare peers using metrics like P/E and EV/EBITDA (30%), and analyst consensus (20%). At the current market price of $0.36, ACUT trades 41.7% below its calculated fair value.

DCF MODEL · 50%

Discounted free cash flow analysis based on projected cash flows, discounted at a rate reflecting ACUT's risk profile.

RELATIVE · 30%

Comparing ACUT's valuation multiples against Healthcare peers to determine if the stock is over or undervalued relative to its industry.

ANALYST · 20%

Aggregated analyst price targets for ACUT, weighted by recency and analyst accuracy.

TRY IT YOURSELF

Want to test your own assumptions? Use our free calculators to estimate ACUT's fair value with your own inputs.

LEARN MORE

Bulios

POWERED BY BULIOS

Get full analysis, financials, and AI insights for ACUT.

Explore on Bulios

FAQ

What is the fair price of ACUT?+

Based on our blended model combining DCF analysis (50%), relative valuation against Healthcare peers (30%), and analyst consensus (20%), the fair price for Accustem Sciences Inc. is $0.51. At the current market price of $0.36, ACUT trades 41.7% below its calculated fair value.

Is ACUT overvalued or undervalued?+

Accustem Sciences Inc. is currently undervalued based on our valuation model. The stock trades at $0.36, which is 41.7% below the fair price of $0.51.

What is the margin of safety for ACUT?+

With a 20% margin of safety applied to the fair price of $0.51, the conservative entry level for ACUT is $0.41. At the current market price of $0.36, the stock trades 13.3% below this entry level. Margin of safety is a risk management concept from Benjamin Graham's value investing framework, not an investment recommendation.

How often is ACUT's fair price updated?+

We update fair price calculations for ACUT daily after market close. The current fair price of $0.51 incorporates the latest market data and sector multiples.

What factors affect ACUT's fair price calculation?+

ACUT's fair price of $0.51 is derived from DCF analysis (50% weight), relative valuation against Healthcare peers (30% weight), and analyst consensus (20% weight)., ROE of 59.1%.

Is ACUT a good buy right now?+

At $0.36, ACUT trades 41.7% below our fair value estimate of $0.51. The stock is currently undervalued. ROE stands at 59.1% (exceptional). Fair Price Index provides valuation data — always do your own research before investing.

Does ACUT pay dividends?+

ACUT does not currently pay a dividend.

RELATED STOCKS

Fair Price Index is for informational purposes only and does not constitute investment advice. Fair value calculations are model-based estimates and may not reflect actual market conditions. Always conduct your own research before making investment decisions.